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Modulation of purinergic signaling, which is critical
for vascular homeostasis and the response to vascular
injury, is regulated by hydrolysis of proinflammatory
ATP and/or ADP by ectonucleoside triphosphate
diphosphohydrolase 1 (ENTPD-1; CD39) to AMP,
which then is hydrolyzed by ecto-5=-nucleotidase
(CD73) to adenosine. We report here that compared
with littermate controls (wild type), transgenic mice
expressing human ENTPDase-1 were resistant to the
formation of an occlusive thrombus after FeCl3-in-
duced carotid artery injury. Treatment of mice with
the nonhydrolyzable ADP analog, adenosine-5=-0-(2-
thiodiphosphate) trilithium salt, Ado-5=-PP[S], negated
the protection from thrombosis, consistent with a
role for ADP in platelet recruitment and thrombus
formation. ENTPD-1 expression decreased whole-
blood aggregation after stimulation by ADP, an effect
negated by adenosine-5=-0-(2-thiodiphosphate) tri-
lithium salt, Ado-5=-PP[S] stimulation, and limited the
ability to maintain the platelet fibrinogen receptor,
glycoprotein IIb/3, in a fully activated state, which
is critical for thrombus formation. In vivo treatment
with a CD73 antagonist, a nonselective adenosine-
receptor antagonist, or a selective A2A or A2B adenos-
ine-receptor antagonist, negated the resistance to
thrombosis in transgenic mice expressing human
322ENTPD-1, suggesting a role for adenosine generation
and engagement of adenosine receptors in conferring
in vivo resistance to occlusive thrombosis in this
model. In summary, our findings identify ENTPDase-1
modulation of purinergic signaling as a key determi-
nant of the formation of an occlusive thrombus after
vascular injury. (Am J Pathol 2012, 181:322–333; http://dx.
doi.org/10.1016/j.ajpath.2012.03.024)
Arterial thrombosis secondary to rupture of an athero-
sclerotic plaque is the underlying event in the majority of
acute myocardial infarctions and the leading cause of
death in the westernized world.1 Atherosclerotic plaque
rupture exposes the subendothelial matrix, which leads
to platelet activation secondary to the convergence of
numerous signaling cascades that release platelet-dense
granules, increasing local concentrations of the puriner-
gic mediators, ATP and ADP.2,3 Engagement of specific
receptors on platelets results in further activation and
recruitment of platelets into the growing thrombus.2,3 Af-
ter thrombotic coronary arterial occlusion, myocardial
ischemia and subsequent necrosis ensues, resulting in
myocardial damage and dysfunction if blood flow is not
restored promptly.
An extracellular purinergic regulatory pathway is posi-
tioned uniquely to modulate thrombosis, inflammation,
and myocardial ischemia-reperfusion injury.4 A key com-
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diphosphohydrolase-1 (ENTPD-1; CD39), a 70- to 100-
kDa transmembrane protein expressed on platelets, en-
dothelium, and leukocytes that hydrolyzes the proinflam-
matory prothrombotic molecules ATP and ADP to AMP.5,6
AMP subsequently is converted by ecto-5=-nucleotidase
(CD73) to the anti-inflammatory, anti-thrombotic, and car-
diac protective compound, adenosine,7 with multiple re-
ceptors existing for ATP, ADP, and adenosine.8,9 Our
laboratory recently showed that ENTPD-1 expression re-
duces myocardial infarct size after ischemia-reperfusion
injury in both mouse and pig.10,11 Furthermore, de-
creased ENTPD-1 activity has been shown in atherec-
tomy specimens from patients with acute coronary syn-
dromes, suggesting a pivotal role for ENTPD-1 in
modulating the balance between a prothrombotic and
antithrombotic milieu.12
Given the complex regulation of the purinergic system
in thrombosis, we hypothesized that overexpression of
ENTPDase-1 may modulate in vivo large-conduit vessel
arterial thrombosis by affecting both platelet reactivity
and tissue factor expression levels. Here, we show that
overexpression of human ENTPDase-1 in mice modu-
lates purinergic signaling, which attenuates activation of
the platelet fibrinogen receptor, glycoprotein IIb/3 (GP
IIb/IIIa; CD41/CD61), and conveys resistance to in vivo
thrombosis not only via hydrolysis of ADP but also through
specific adenosine-receptor engagement.
Materials and Methods
Transgenic Mice
The generation of the human ENTPDase-1–expressing
mice has been described previously.13 The human
ENTPD-1 (CD39) transgene is expressed from the mouse
H-2Kb promoter, resulting in global expression of
ENTPD-1 in these mice. Transgenic mice expressing hu-
man (ENTPD-1-Tg) were back-crossed for more than 10
generations onto the BALB/c background and compared
with littermate controls. The investigations described
conform to the Guidelines for the Care and Use of Lab-
oratory Animals of the National Institutes of Health and
were approved by The Ohio State University Institutional
Animal Care and Use Committee.
Chemicals
The following inhibitor of CD73 activity was used in
these studies: --methylene-ADP (APCP; Sigma-Al-
drich, St. Louis, MO).14 The following chemical antag-
onists of adenosine receptors were used in this
study15,16: 8-(p-sulfophenyl) theophylline (8-SPT), a
nonselective antagonist for adenosine receptors A1,
A2A, A2B, and A3 (Sigma-Aldrich); 4-(2-[7-amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)
phenol (ZM 241385), a highly selective A2A adenosine
antagonist (Tocris, Ellisville, MI); N-(4-cyanophenyl)-2-[4-
(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-
phenoxy]acetamide (MRS 1754), a selective A2B-
receptor antagonist (Sigma-Aldrich). The following ADPmimetic, adenosine-5=-0-(2-thiodiphosphate) trilithium
salt, Ado-5=-PP[S] (ADP--S; Sigma-Aldrich) was used.15
In Vivo Carotid Thrombosis
Ferric chloride (FeCl3)-induced carotid artery thrombosis
was used.17 Wild-type (WT) or ENTPD-1-Tg mice were
anesthetized with ketamine (55 mg/kg) plus xylazine (15
mg/kg). Atropine (0.05 mg s.c.) was administered to re-
duce airway secretions. Animals were intubated and ven-
tilated with room air (tidal volume, 250 L; 150 breaths/
minute) with a mouse respirator (Harvard Apparatus,
Holliston, MA). Rectal temperatures were maintained at
37°C by a thermo-regulated heating pad. The left com-
mon carotid artery was dissected gently, a flow probe
was placed on the artery (MA0.5PSB; Transonic Systems;
Ithaca, NY), and blood flow was measured with a pulsed
Doppler flow system. After obtaining baseline flow re-
cordings, carotid artery injury was induced by application
of filter paper saturated with 10% FeCl3 solution on the
adventitial surface proximal to the flow probe for 3 min-
utes. The flow as a percentage of baseline and the time to
thrombotic occlusion (blood flow, 0 mL/minute) was mea-
sured from the placement of the FeCl3-saturated filter
paper. The surgeon was blinded to the animal genotype
and any drug treatment during all experiments. Animals
were reanesthetized as needed and at each hour un-
der anesthesia the animals were administered normal
saline intraperitoneally. For those animals treated with
pharmacologic antagonists, the antagonists were dis-
solved in a final concentration of 0.5% dimethyl sulfox-
ide and administered at the designated dose as a
single intraperitoneal injection 15 to 30 minutes before
the application of FeCl3.
For visualization of thrombus formation, mice were
injected intravenously with 5 L of a 100-mol/L solu-
tion/gram of body weight of the cationic lipophilic dye
3,3=-dihexyloxacarbocyanine iodide 10 minutes before
application of FeCl3 to induce vessel injury.
18 The ca-
rotid artery was video recorded continuously using a
Leica M165 FC fluorescent stereomicroscope (Leica,
Wetzlar, Germany) equipped with a Hamamatsu
ORCA-R2 Digital CCD camera (Hamamatsu, Hamamatsu
City, Japan) for 30 minutes.
Carotid Histology
At 15 minutes after the application of FeCl3 animals
were perfusion-fixed with 4% buffered paraformalde-
hyde and the injured and noninjured carotid arteries
from WT or ENTPD-1-Tg mice were isolated. The sam-
ples were embedded in paraffin, sectioned at 3 m,
and stained with H&E.
Whole-Blood Aggregation
Blood was collected from the inferior vena cava of anes-
thetized WT or ENTPD-1-Tg mice into 70 U/mL of sodium
heparin and then diluted 1:2 into physiological saline and
whole-blood aggregometry was performed on these di-
luted samples.19 One milliliter of diluted blood was
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37°C in the Chrono-Log Whole Blood Lumi-Ionized Cal-
cium Aggregometer (Chrono-Log Corp., Havertown, PA).
The cuvettes then were placed into the test chamber
and incubated with the impedance electrode at 37°C
while stirring at 900 rpm. After 2 minutes of stabiliza-
tion, ADP (20 mol/L final concentration; Chrono-Log
Corp., Havertown, PA) or ADP--S (20 mol/L final
concentration; Sigma-Alrich) was added. Aggregation,
measured as ohms of electrical impedance, was re-
corded for up to 6 minutes. All whole-blood aggregom-
etry tests were performed within 2 hours of blood ac-
quisition.
Flow Cytometric Analysis
Whole blood was obtained from the inferior vena cava of
anesthetized WT or ENTPD-1-Tg–expressing mice. All
antibodies were obtained from EMFRET Analytics GmbH
& Co. KG (Eibelstadt, Germany). Whole-blood fluores-
cence-activated cell sorting analysis for the levels of the
total fibrinogen receptor, glycoprotein IIb/3 complex
expression (clone Leo.H4; Rat IgG2b), was examined at
baseline to ensure that there was no difference in the
level of these critical platelet membrane proteins involved
in platelet activation and thrombosis. Platelet activation
was analyzed by activation of diluted whole blood with 20
mol/L ADP and activated GP IIb/3 complex (clone
JON/A; Rat IgG2b)
20 expression was examined by flow
cytometric analysis at specified times to examine the
level of platelet activation (BD LSR II Flow Cytometer;
Becton Dickinson, Franklin Lakes, NJ). Nonspecific stain-
ing was determined with isotype control antibodies.
ENTPDase Activity Assay
Total platelet lysates were assayed for ENTPDase activity
as previously described.13 One unit of ATP diphospho-
hydrolase activity corresponds to the release of 1 mol
inorganic phosphate/minute at 37°C.21
Quantification of Vascular Tissue Factor
Expression and Platelet P2Y1- and
P2Y12-Receptor Levels
Vascular tissue factor (TF) was measured semiquantita-
tively using Western blot analysis as published previ-
ously.22 Aortas were removed, cleaned of adventitia,
placed in ice-cold phosphate-buffered saline, and then
homogenized using an Omni tissue homogenizer (model
TH-794; Omni International, Marietta, GA) in lysis buffer
consisting of 30 mmol/L 3-[(3-cholamidopropyl)dimethyl-
ammonio]propanesulfonic acid, 10 mol/L E64, 1 mmol/L
phenylmethylsulfonyl fluoride, and 10 mmol/L EDTA in
PBS (pH 7.4). For platelet homogenates, whole blood
was obtained from the inferior vena cava of anesthetized
WT or ENTPD-1-Tg–expressing mice, diluted 1:1 in phys-
iological saline, and layered onto platelet Fico/Lite (At-
lanta Biologicals, Lawrenceville, GA). Platelet-rich
plasma was generated by centrifugation at 350 g for 15minutes. Platelets then were washed with physiological
saline and pelleted. Samples from 3 mice were pooled
and homogenized in lysis buffer consisting of 50 mmol/L
Tris (pH 7.4), 150 mol/L NaCl, 0.5% Nonidet P-40, 1
mmol/L sodium pyrophosphate, 5 mmol/L sodium vana-
date, 1 mmol/L benzamidine, and 1 mmol/L sodium fluo-
ride with protease inhibitor cocktail (Sigma-Aldrich).
The crude homogenates were centrifuged at 10,000 g,
and supernatants were transferred and stored at 80°C
until analyzed. Protein content of supernatants was mea-
sured using the DC protein assay (Bio-Rad Laboratories,
Hercules, CA). Equal amounts of protein (12 g for TF, 15
g for P2Y1 and P2Y12) were diluted 1:2 in Laemmli
sample buffer (Bio-Rad) and placed in a boiling water
bath for 5 minutes. Samples then were run on 12.5%
Criterion ready gels (Bio-Rad) using SDS-PAGE, proteins
were transferred to polyvinylidene difluoride membranes,
and blocked overnight in Tris-buffered saline (pH 7.4)
with 0.05% Tween 20 (Sigma-Aldrich) and 5% powdered
milk. Membranes were incubated with primary antibodies
to mouse TF (1:500, 12 hours; American Diagnostica,
Stamford, CT) or mouse P2Y12 receptor (1:1000, 12
hours; AnaSpec, Freemont, CA), mouse P2Y1 (1:400, 12
hours; Alomone, Jerusalem, Israel), or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (1:15,000, 12 h;
Abcam, Inc, Cambridge, MA), and after washing were
incubated for 45 minutes with horseradish-peroxidase–
conjugated secondary antibody. Immunoblots were de-
veloped using Supersignal (Pierce, New Haven, CT) and
quantified by densitometry (ChemiDoc; Bio-Rad). TF,
P2Y1, and P2Y12 were normalized to GAPDH and data
are presented as the relative quantification of TF P2Y1
and P2Y12 (relative to each individual sample GAPDH).
Statistical Analysis
The results of experiments were analyzed by several
statistical methods using standard software (eg,
GraphPad Prism, version 4.0, San Diego, CA). Results
were expressed as mean  standard error of the mean.
For comparison between 2 groups, significance was de-
termined by an unpaired Student’s t-test. For comparison
of multiple groups, multifactorial analysis of variance with
post hoc comparison of the means with Bonferroni cor-
rection was used to determine statistical significance. For
all evaluations, probability values less than 0.05 were
considered significant.
Results
Overexpression of ENTPDase-1 Markedly
Delays Formation of Occlusive Thrombus
Formation in Vivo
Analysis of platelets from human ENTPDase-1–express-
ing mice revealed a twofold increase in ENTPDase activ-
ity and increased surface level expression of ENTPD-1
compared with WT control platelets consistent with a
prior study showing increased expression on the plate-
lets, endothelium, and leukocytes of the transgenic mice
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shown).13 No differences in the complete blood count
were observed between WT and ENTPD-1-Tg mice
(Table 1). To determine whether ENTPDase-1 overex-
pression translated to a resistance to in vivo conduit artery
thrombosis, WT or ENTPD-1-Tg mice were evaluated in a
model of FeCl3-induced carotid artery thrombosis.
17 In
WT animals there was an initial increase in carotid flow
followed by a precipitous decrease in flow to zero that
correlated in vivo with the formation of an acute occlusive
thrombus. However, in ENTPD-1–expressing animals, al-
though there was no increase in flow observed after ferric
chloride application and there was a gradual decrease in
carotid flow to approximately 70% of the baseline flow, no
occlusive thrombus was formed within the injured vessel
(Figure 1, A and B). These findings were confirmed by
histologic assessment of the carotid arteries after
FeCl3 treatment that revealed occlusive thrombus
present in the injured WT animals by 15 minutes, but
not in the injured carotid arteries of ENTPD-1-Tg ani-
mals (data not shown).
To determine the absolute extension of the time to
thrombosis conveyed by ENTPD-1 expression, a sepa-
rate group of animals was monitored until occlusion was
observed. ENTPD-1 expression profoundly delayed the
time to occlusion (WT: 13.7  0.88 minutes, N  14
versus ENTPD-1-Tg: 281.5  57.31 minutes, N  8; P 
0.001; Figure 1C). Given the role of TF in ferric chloride–
induced carotid thrombosis,23–26 as well as prior studies
showing an increase in TF levels in ENTPD-1 knockout
mice27 and decreased expression of TF on endothelial
cell cultures treated with adenosine,28 the level of TF in
the vasculature was measured and found not to differ
between WT and ENTPD-1-Tg aortae at baseline (relative
TF/GAPDH densitometric ratios were as follows: WT,
0.20  0.044; ENTPD-1-Tg, 0.21  0.033; P  0.05; N 
3 per group; Figure 1D). Furthermore, strain variations with
Table 1. Complete Blood Count from WT and ENTPD-1-Tg
Mice
Parameter WT (n  6) ENTPD-1-Tg (n  6)
WBC (K/L) 5.7  0.8 7.5  1
NE (%) 26.9  1.6 25.6  1.6
LY (%) 60.7  2.1 61.7  1.7
MO (%) 9.2  1.2 9.6  1.2
EO (%) 2.4  0.3 2.4  0.6
BA (%) 0.8  0.2 0.6  0.1
HCT (%) 51.9  5.3 54.9  5.4
RBC (K/L) 10.1  1.0 10.8  1.2
Hb (g/dL) 17.1  0.8 16.2  0.8
MCV (fL) 51.4  0.4 51.2  0.8
MCHC (g/dL) 34.2  2.6 30.9  3.0
RDW (%) 15.4  0.2 15.6  0.3
Retics (%) 1.3  0.2 1.1  0.4
PLT (K/L) 1295.7  52.6 1128.7  98.5
MPV (fL) 5.3  0.1 5.1  0.2
None of the data were found to be statistically significantly different.
BA, basophills; EO, eosinophils; Hb, hemoglobin; HCT, hematocrit; LY,
lymphocytes; MCHC, mean corpuscular hemoglobin concentration; MCV,
mean corpuscular volume; MO, monocytes; MPV, mean platelet volume;
NE, neutrophils; PLT, platelets; RBC, red blood cells; RDW, red cell
differential width; Retics, reticulocyte; WBC, white blood cells.regard to coagulation and thrombosis parameters did notaccount for the resistance to occlusive thrombus formation
because C57BL/6 background mice overexpressing hu-
man ENTPD-1 showed a comparable prolongation in the
time to thrombosis (data not shown). Thus, overexpression
of ENTPD-1 conveys a marked protection against the gen-
eration of an occlusive arterial thrombus in vivo.
ADP-Receptor Engagement in ENTPDase-1–
Mediated Resistance to Thrombosis
As stated earlier, ENTPDase-1 sequentially converts extra-
cellular ATP and ADP to AMP. ADP is a potent platelet
agonist required for the continued expression of activated
glycoprotein IIb/3-complex. To determine whether the
ENTPDase-1–mediated in vivo resistance to thrombosis in-
volved ADP hydrolysis, animals were treated with the non-
hydrolyzable ADP analog (ADP--S). Treatment with 6.25
mg/kg ADP--S, administered intravenously, 10 minutes
before the application of ferric chloride, resulted in abroga-
tion of the antithrombotic efficacy observed in ENTPD-
1-Tg mice (ADP--S–treated mice: WT: 11.3  1.53 min-
utes versus ENTPD-1-Tg: 17.1  2.59 minutes; P  0.05;
N  3 per group; Figure 1C), consistent with the inter-
pretation that hydrolysis of ADP is the critical step in the
protection from in vivo thrombosis in ENTPD-1-Tg mice.
ENTPDase-1 Modulates ex Vivo Platelet
Aggregation and Activation
To examine the effect of ENTPD-1 overexpression in an
ex vivo model, whole-blood aggregation was performed.
In response to ADP stimulation (20 mol/L), both WT and
ENTPD-1-Tg whole blood displayed a rapid initiation of
aggregation that persisted in WT blood. In contrast, al-
though an initial aggregatory response was observed
after ADP stimulation, there was a rapid and near-com-
plete disaggregation observed in ENTPD-1-Tg whole
blood (Figure 2A). This resulted in a decrease in the total
area under the curve in response to 20 mol/L ADP
stimulation in ENTPD-1-Tg versus WT (area under the
curve was as follows: WT: 20,900  746.2  · seconds;
ENTPD-1-Tg: 5586  1544  · seconds; N  4 per
group; P  0.0001) and a decrease in the total aggrega-
tion at 6 minutes (Figure 2B; aggregation at 6 minutes:
WT: 69.8  6.35 ; N  4 per group: ENTPD-1-Tg: 4.5 
1.55 ; N  4 per group; P  0.001). These results differ
slightly from what was reported previously for the trans-
genic mice on a different genetic background using
whole blood anticoagulated with citrate.13 Heparin, an in
vivo anticoagulant frequently used in the treatment of
acute coronary syndromes, may increase platelet re-
sponsiveness to agonists.29 However, regardless of the
anticoagulant used, the data are consistent with the in-
terpretation that ENTPD-1 expression inhibits platelet re-
activity in whole blood. Next, to determine whether the
differences in whole-blood aggregation are caused by
ADP hydrolysis, whole blood from ENTPD-1-Tg mice was
stimulated with ADP--S (20 mol/L), which resulted in a
persistent aggregatory response in ENTPD-1-Tg whole
blood compared with ADP stimulation with a correspond-
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2C; ADP: 5358  443.7  · second; ADP--S: 15,380 
680.2  · second; N  3 per group; P  0.0002) and an
increase in the total aggregation at 6 minutes (Figure 2D;
ADP: 1.5  0.75 ; N  3 per group; ADP--S: 55.8 
3.38 ; N  3 per group; P  0.0001), consistent with
ENTPDase-1–mediated hydrolysis of ADP inhibiting the
whole-blood aggregation.
To investigate the effects of overexpression of ENTPD-1
further, platelet activation in whole blood from either WT
or ENTPD-1-Tg mice treated with ADP was compared.
Prior studies have shown a time-dependent increase in
activated platelet fibrinogen receptor, the integrin glyco-
protein (GP) IIb/3 (CD41/CD61) with ADP stimulation.
20
Basal expression levels of GPIX, GPVI (not shown), and
the integrin glycoprotein IIb/3 did not differ between WT
and ENTPD-1-Tg platelets (Figure 3, A and B). Although
ADP stimulation resulted in an increase in surface ex-
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stimulation of WT or ENTPD-1 blood with ADP--S
showed comparable expression of activated GP IIb/3
on platelets at 6 minutes after stimulation (mean fluores-
cence intensity was as follows: WT: 207.3 22.41 versus
ENTPD-1: 229.0 22.94; P 0.05), consistent with intact
expression and signaling mechanism via P2Y1 and P2Y12
receptors in ENTPD-1 platelets. Furthermore, to deter-
mine whether differences in the level of P2Y1- and P2Y12-
receptor expression on platelets from ENTPD-1-Tg mice
contributed to the observed effects, immunoblot analysis
was conducted. No differences in either P2Y1 (relative
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Figure 1. ENTPD-1 conveys resistance to in
vivo thrombosis. A: Carotid flow after FeCl3 ap-
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vivo real-time fluorescence imaging of thrombus
formation in WT and ENTPD-1-Tg animals after
FeCl3 application. C: Time to thrombosis after
FeCl3 application in WT and ENTPD-1-Tg mice
(WT: 13.7  0.9 minutes; ENTPD-1-Tg: 281.5 
57.3 minutes; N  8 per group) and the effect of
ADP--S treatment on the time to thrombosis
after FeCl3 application in WT and ENTPD-1-Tg
mice (ADP- -S: WT: 11.3  1.53 minutes versus
ENTPD-1-Tg: 17.1  2.59 minutes; N  3 per
group). D: Tissue factor expression on aortae
from WT and ENTPD-1 mice. Representative im-
munoblot and normalized densitometry (relative
TF/GAPDH densitometric ratios: WT: 0.20 
0.044; ENTPD-1-Tg: 0.21  0.033; P  0.85; N 
3 per group). Values are mean  standard error
of the mean. *P  0.001; †P  0.05; TG, ecto-
nucleoside triphosphate diphosphohydrolase-1
expressing animals.24
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AJP July 2012, Vol. 181, No. 13 per group; Figure 3E) were observed. Together with the
in vivo data of treatment of mice with ADP--S, these data
suggest that ENTPD-1 activity mediates antiaggregatory
efficacy by hydrolyzing ADP, thus limiting the activation
state of platelet glycoprotein IIb/3, preventing the acute
generation of an occlusive thrombus in vivo.
Adenosine in ENTPDase-1–Mediated
Resistance to Occlusive Thrombosis
As outlined earlier, ENTPDase-1 converts extracellular
ATP and ADP to AMP and ecto-5=-nucleotidase (CD73)
converts extracellular AMP to adenosine, which can reg-
ulate platelet reactivity and in vivo thrombosis.30,31 To
determine whether the in vivo resistance to carotid throm-
bosis observed in ENTPD-1-Tg animals also involves the
generation of adenosine by ecto-5=-nucleotidase, mice
were treated with APCP, a specific ecto-5=-nucleotidase
antagonist. Treatment with APCP also abrogated the re-
sistance to occlusive thrombus formation mediated by
ENTPD-1 overexpression (APCP-treated WT: 11.9 1.01
minutes versus APCP-treated ENTPD-1-Tg: 15.5  1.08
minutes; N  4 per group; P  0.05; Figure 4, A and B),
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lation of AMP, or that ecto-5=-nucleotidase–mediated
generation of adenosine is involved in the in vivo resis-
tance to thrombosis.
To address if adenosine-receptor–mediated signaling
contributes to the resistance to in vivo thrombosis ob-
served in ENTPDase-1–expressing mice, mice were
treated with the nonselective adenosine-receptor antag-
onist 8-SPT. Treatment with 8-SPT abrogated the resis-
tance to occlusive thrombus formation observed in mice
overexpressing ENTPDase-1, consistent with the inter-
pretation that adenosine receptor engagement is re-
quired for the resistance to occlusive thrombus formation
mediated by ENTPDase-1 (8-SPT–treated WT: 10.5 
1.42 minutes versus 8-SPT–treated ENTPD-1-Tg: 14.3 
1.57 minutes; N  8 per group; P  0.05; Figure 4, A and
C). Thus, APCP and 8-SPT, both with distinct molecular
structures, either inhibit ENTPDase-1 activity directly or
these pharmacologic data are consistent with an inter-
pretation that, in the mouse, generation of adenosine and
engagement of adenosine receptors contributes to the in
vivo antithrombotic efficacy conveyed with ENTPD-1
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whole-blood aggregation in ENTPDase-1 mice.
A: Whole-blood aggregation curve in response
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blood. Area under the curve for whole-blood
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blood in response to 20 mol/L ADP (WT:
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4 per group). ADP--S restores whole-blood ag-
gregation in ENTPDase-1 mice. C: Whole-blood
aggregation in ENTPD-1-Tg blood in response to
20 mol/L ADP or 20 mol/L ADP--S, a non-
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AJP July 2012, Vol. 181, No. 1ters platelet reactivity via interaction with the A2A recep-
tor. To delineate if occupation of the adenosine A2A re-
ceptor is involved in the ENTPDase-1–mediated
resistance to thrombosis, the acute effect of ZM 241385,
a selective antagonist of the A2A-adenosine receptor,
was examined. Acute pretreatment of mice with ZM
241385 completely abrogated the in vivo resistance to
thrombosis conveyed by ENTPDase-1 overexpression,
consistent with an interpretation that the in vivo ENTP-
Dase-1–mediated effects require A2A-receptor occu-
pancy (ZM 241385 1 mg/kg: WT: 11.1  0.58 minutes
versus ENTPD-1: 14.4  1.31 minutes; N  5 per group;
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D EP  0.05; Figure 4, D and E). Given recent data suggest-ing an inhibitory role of adenosine A2B-receptor activation
on platelet reactivity ex vivo,32 the effect of MRS 1754, a
selective A2B-receptor antagonist, also was examined. At
all doses examined, pretreatment with MRS 1754 (0.1
mg/kg) abrogated the resistance to thrombosis achieved
with ENTPD-1 overexpression (0.1 mg/kg MRS 1754–
treated: WT: 12.3  1.88 minutes versus ENTPD-1-Tg:
20.5  11.05 minutes; P  0.05; N  5 per group; Figure
4, D and F), consistent with the interpretation that aden-
osine A2B-receptor occupation also is required for the in
vivo ENTPDase-1–mediated resistance to thrombosis.
Thus, 8-SPT, ZM 241385, or MRS 1754, all structurally
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the interpretation that, in the mouse, engagement of both
the A2A and A2B adenosine receptors contribute to the
antithrombotic efficacy conveyed with ENTPD-1 expres-
sion.
Discussion
Acute arteriosclerotic plaque rupture with subsequent
adhesion and aggregation of platelets results in throm-
bus formation and coronary vessel occlusion, the patho-
physiologic basis of acute coronary syndromes.1 The
current studies show that increased ENTPD-1 (CD39)
activity can modulate purinergic signaling, thereby atten-
uating activation of the platelet fibrinogen receptor, the
integrin GP IIb/3 (CD41/CD61), resulting in a profound
resistance to in vivo occlusive thrombus formation. In-
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veys a marked protection against in vivo arterial thrombosis
and treatments aimed at increasing ENTPD-1 levels might
convey vascular protection.
The accumulation of platelets at sites of vascular dis-
ruption via engagement of specific platelet receptors to
the exposed subendothelial matrix leads to platelet acti-
vation. On activation, numerous signaling cascades con-
verge to release of ATP and ADP from platelet-dense
granules, which further activate and recruit platelets into
the growing thrombus. ATP and ADP also affect vascular
reactivity, inducing vasodilation when administered ablu-
minally to intact carotid arteries.33 ENTPDase-1 appears
to control nucleotide-dependent vasoconstriction be-
cause knockout of the ENTPDase-1 gene leads to in-
creased aortic ring constriction in response to UDP or
UTP.34,35 Thus, ATP and ADP mediate prothrombotic and
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Figure 4. Adenosine in ENTPDase-1–medi-
ated resistance to occlusive thrombosis. A:
Administration of the ecto-5=-nucleotidase in-
hibitor APCP or the nonselective adenosine re-
ceptor antagonist 8-SPT abrogates ENTPDase-
1–mediated resistance to occlusive thrombus
formation in vivo (APCP-treated WT: 11.9 
1.01 minutes; APCP-treated ENTPD-1-Tg:
15.5  1.08 minutes; N  4 per group, P 
0.045 versus APCP-treated WT; P  0.001 ver-
sus untreated ENTPD-1-Tg; 8-SPT–treated WT:
10.5  1.42 minutes; 8-SPT–treated ENTPD-1-
Tg: 14.3  1.57 minutes; N  8 per group, P 
0.05 versus 8-SPT–treated WT; P  0.001 ver-
sus untreated ENTPD-1-Tg). B: Carotid flow
after FeCl3 application expressed as a percent-
age of baseline flow in WT and ENTPD-1-Tg
animals treated with APCP. C: Carotid flow af-
ter FeCl3 application expressed as a percentage
of baseline flow in WT and ENTPD-1-Tg ani-
mals treated with 8-SPT. D: Administration of
the adenosine A2A-receptor antagonist ZM
241385 or the adenosine A2B-receptor antago-
nist MRS-1754 abrogates ENTPDase-1–medi-
ated resistance to occlusive thrombus forma-
tion in vivo (ZM-treated WT: 11.1  0.58
minutes; ZM 241385-treated ENTPD-1-Tg:
14.4 1.31 minutes; N 5 per group, P 0.05
versus ZM 241385-treated WT; P  0.001 ver-
sus untreated ENTPD-1-Tg; MRS-1754–treated
WT: 12.3  1.88 minutes; MRS-1754–treated
ENTPD-1-Tg: 20.5  11.05 minutes; N  5 per
group, P  0.05 versus MRS-1754–treated WT;
P  0.001 versus untreated ENTPD-1-Tg). E:
Carotid flow after FeCl3 application expressed
as a percentage of baseline flow in WT and
ENTPD-1-Tg animals treated with ZM 241385.
F: Carotid flow after FeCl3 application ex-
pressed as a percentage of baseline flow in WT
and ENTPD-1-Tg animals treated with MRS-
1754. Values are mean  standard error of the
mean. *P  0.05; TG, ectonucleoside triphos-
phate diphosphohydrolase-1 expressing animals.is (min
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muscle, platelets, and inflammatory cells.34–36 Modula-
tion of platelet function is achieved in part through the
action of several purinergic receptors on platelets, P2Y1,
P2Y12, and P2X1.
36
The P2Y1 is a Gq G-protein–coupled receptor critical
to ADP-induced shape change, aggregation, thrombox-
ane A2 generation, and thrombus formation under shear
conditions.37–39 Knockout of the P2Y1 receptor results in
absence of platelet shape change and reduced aggre-
gation in response to ADP as well as reduced thrombus
size and stability.40,41 Overexpression of the P2Y1 recep-
tor results in increased platelet reactivity both ex vivo and
in vivo.42 The P2Y12 receptor is a Gi-coupled G-protein–
coupled receptor that suppresses cAMP formation,43
thereby potentiating platelet activation by a number of
stimuli.36 Knockout of the P2Y12 receptor results in re-
duced ADP-induced platelet aggregation, an inability to
inhibit adenylyl cyclase activity, and prolonged bleeding
time, however, platelet shape change and intracellular
aggregation are not affected.44,45 Interestingly, the P2Y12
receptor, the target of the clinically approved antiplatelet
agents clopidogrel and prasugrel, has a lower affinity for
ADP than the P2Y1 receptor. Furthermore, the prodrug
form of clopidogrel appears to facilitate platelet aggre-
gation by inhibition of ENTPDase-1.46 In contrast to the
P2Y1 and P2Y12 receptors, the P2X1 receptor is stimu-
lated by ATP, resulting in an influx of calcium that does
not lead to aggregation but is necessary for full activation
of platelets. Knockout of the P2X1 receptor results in
resistance to thrombosis of small arteries,42 whereas
overexpression of P2X1 receptors results in increased
thrombus formation in response to various agonists.47
Thus, genetic studies have shown that activation of each
of the purinergic receptors is necessary for full platelet
activation.
In the current study, increased ENTPDase-1 activity
reduced ADP-mediated whole-blood aggregation. Simi-
larly, in response to ADP activation, ENTPDase-1 expres-
sion decreased activation of the platelet fibrinogen re-
ceptor, GP IIb/3 complex. These data are consistent
with prior work showing that persistent ADP-mediated
P2Y1- and P2Y12-receptor stimulation is required to main-
tain calcium-mediated activation of the platelet fibrinogen
receptor, glycoprotein IIb/3.
48 Thus, ENTPDase-1 not
only maintains basal vascular function, but in pathologic
states, ENTPDase-1–mediated hydrolysis of ATP and
ADP released from damaged tissue regulates the puri-
nergic pathways involved in platelet activation and throm-
bosis. However, the antithrombotic effects conveyed by
ENTPD-1 expression were reversed by stimulation with
the nonhydrolyzable ADP analog, ADP--S, suggesting
that continued ADP stimulation is required to maintain
maximal aggregation and platelet activation, a well-
known phenomenon,49–52 and that P2Y1 and P2Y12 ex-
pression and signaling are intact and capable of medi-
ating platelet activation in ENTPD-1 platelets.
ATP and ADP are metabolized to AMP, which is con-
verted to adenosine by the actions of ecto-5=-nucleoti-
dase (CD73). Recent work has shown that soluble 5=-
nucleotidase derived from Crotalus atrox venom inhibitsex vivo platelet aggregation, suggesting a role for ade-
nosine-mediated signaling in the inhibition of platelet
function.53 However, in our current model, we observed
no effect with antagonism of ecto-5=-nucleotidase or of
adenosine-receptor blockade in whole-blood aggrega-
tion (data not shown). Indeed, prior studies have
shown no effect of adenosine on whole-blood aggre-
gation except under conditions in which dipyridamole
is added to prevent red blood cell uptake and metab-
olism of adenosine.54–56
The current data suggest that in our model inhibition of
whole-blood aggregation is dependent on ADP degrada-
tion rather than adenosine generation. However, a more
complex situation appears to be involved in the cascade
leading to in vivo thrombosis in which both ADP degra-
dation and adenosine generation via ecto-5=-nucleoti-
dase (CD73) activity appear capable of modulating oc-
clusive thrombus formation after arterial injury. Indeed,
prior studies31 have demonstrated that endogenous
adenosine production appears to inhibit in vivo platelet
aggregation. It has been proposed that localized effects
might explain the observation reported here and in other
studies regarding adenosine modulation of platelet acti-
vation and thrombus growth in vivo; adenosine-receptor
effects may be more pronounced in pathologic pro-
cesses, such as a growing thrombus.56 In our in vivo
model, ENTPD-1–mediated resistance to formation of an
occlusive thrombus appears dependent on ecto-5=-nu-
cleotidase activity because treatment of ENTPD-1-Tg
mice with the CD73 antagonist APCP normalized the time
to thrombosis. These data are consistent with prior stud-
ies that have shown that knockout of ecto-5=-nucleotidase
results in a shortened time to thrombosis in a murine
model of FeCl3-induced carotid arterial thrombosis.
57 Fu-
ture studies examining the effect of genetic ablation of
ecto-5=-nucleotidase in mice that overexpress ENTP-
Dase-1 will provide further insight into this complex sig-
naling cascade both ex vivo and in vivo. Our data suggest
that not only ADP hydrolysis but also adenosine genera-
tion are necessary for ENTPD-1–mediated resistance to
in vivo occlusive thrombus formation after vascular in-
jury. Thus, therapies that lead to increased ENTPD-1
activity may have profound vascular protective effi-
cacy.
Platelets possess both A2A adenosine receptors and
A2B adenosine receptors,
58,59 and both couple to ade-
nylate cyclase, causing an increase in cAMP levels,
which inhibits platelet activation.60,61 Genetic ablation of
either the A2A adenosine receptor
58 or the A2B adenosine
receptor32 results in higher platelet aggregation in re-
sponse to ADP. The A2A and A2B adenosine receptors
also are expressed on circulating neutrophils and mono-
cytes. Indeed, not only platelet-platelet interactions but
also platelet-leukocyte adhesion occur with acute arterial
injury; circulating platelet-leukocyte aggregates are in-
creased in acute coronary syndromes.62 Thus, one might
hypothesize that ENTPDase-1 expression on leukocytes
may modulate platelet/leukocyte interactions and affect
thrombosis. Prior studies have shown that in patients with
leukocytosis, ENTPDase-1 activity is increased and platelet
aggregation is reduced in response to various stimuli.63
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regulate the level of expression of ENTPDase-1 on leuko-
cytes.64 Furthermore, ENTPDase-1 regulates leukocyte
chemotaxis by hydrolyzing released ATP to adenosine,
which coordinate to modulate chemotaxis via activation
of purinergic nucleotide and adenosine receptors,65–70
and modulates P2X purinoreceptor 7–dependent func-
tion in murine macrophages.71 The regulation of TF pro-
coagulant activity is complex, with a number of pathways
capable of switching TF from a cryptic, nonactive state, to
a decrypted, active state.72 Recent work has shown a
critical role for activation of the macrophage P2X purino-
receptor 7 in a protein disulfide isomerase-regulated thiol
pathway that controls the release of procoagulant TF–
positive microparticles and also TF-dependent thrombo-
sis.26 Although the level of TF does not differ between WT
and ENTPD-1-Tg aortae, further work will be required to
determine whether ENTPDase-1 influences TF decryption.
Indeed, ongoing work is investigating the influence of the
cellular expression of ENTPDase-1 on in vivo thrombosis.
In conclusion, these results show a pivotal role of ec-
tonucleoside triphosphate diphosphohydrolase-1 in the
modulation of purinergic-mediated platelet activation.
ENTPDase-1 expression results in an attenuation of acti-
vation of the platelet fibrinogen receptor, glycoprotein
IIb/3, which translates to a resistance to in vivo occlu-
sive thrombus formation. Our data suggest that not only
ADP removal, but also adenosine-receptor engagement,
delays in vivo thrombosis because antagonism of CD73
or nonselective adenosine-receptor antagonism abro-
gates the resistance to occlusive thrombus formation
conveyed by ENTPDase-1 expression. Supporting our
work is recent data showing that in mice subjected to
hypothermia, a condition used frequently to treat patients
with out-of-hospital arrest, ENTPDase-1 activity was de-
creased, expression of the platelet activation marker P-
selectin was increased, and platelet thrombus formation
in FeCl3-injured murine mesenteric arteries was in-
creased.73 These effects were reversed by administra-
tion of recombinant soluble ENTPD-1.73 We acknowledge
that a limitation of the current studies was the specificity
and selectivity of the pharmacologic agents used and
that the generalizability of the current findings to other
models of vascular injury cannot be inferred. However,
the ferric chloride model has been used to show the
efficacy of agents used clinically to treat acute arterial
thrombosis, including tirofiban, eptifibatide, and clopi-
dogrel.17,74 Continuing investigations using in vivo
thrombus imaging, alternate methods of arterial vascu-
lar injury, and adenosine-receptor knockout animals
will help define the interplay between ENTPDase-1 ac-
tivity and adenosine receptor–mediated signaling on
platelet activation and in vivo thrombus formation and
stability further. The current data show that ENTPDase-
1–mediated modulation of purinergic signaling is a key
determinant of the formation of an occlusive arterial
thrombus after vascular injury and supports the hy-
pothesis that therapy focused on increasing ENTPD-1
expression and activity could have profound in vivo
antithrombotic efficacy.Acknowledgments
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